Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Reports-Positive-Topline-Data-from-Phase-2-Study-of-CYB003-in-Major-Depressive-Disorder-with-79-of-Patients-in-Remission-after-Two-12mg-Doses/default.aspx